Clinical Trial Update: The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY [NA]

View source ↗

Summary

ClinicalTrials.gov reports ongoing recruitment for a University of Toronto study evaluating TACK, a T-cell activator therapy, for HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TACK (T-cell activator (TACK))

Snippet

Sponsor: University of Toronto | Conditions: Hiv | NA | Status: RECRUITING